{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '12. The ADA samples for immunogenicity are collected pre-infusion on day 1 of cycle 1, 3, 7,', '11, and 15. The ADA samples for immunogenicity are to be obtained only from patients', 'randomized to receive cemiplimab.', '13. The biomarker samples are collected pre-infusion on day 1 of cycles 1 through 8.', '14. Peripheral blood mononuclear cell (PBMC) collection is optional. If pre-treatment PBMC', 'is not collected on day 1/cycle 1, PBMC should not be collected at future dates. If PBMC', 'are collected, this sample should be collected prior to treatment on day 1 of cycles 1 through', '3. Samples are to be obtained only from patients randomized to receive cemiplimab.', '15. The EORTC QLQ-C30 assessment may be performed at any subsequent visit within the', 'same treatment cycle if the assessment is not performed on day 1.', '7.1.3.', 'Unscheduled Visits', 'All attempts should be made to keep patients on the study schedule. Unscheduled visits may be', 'necessary to repeat testing following abnormal laboratory results, for follow-up of AEs, or for any', 'other reason, as warranted.', '7.1.4.', 'Post-Treatment Follow-Up', 'Table 2:', 'Schedule of Events, Post-Treatment Follow-Up', 'Follow-up Visits 1', 'Survival Follow-Up', 'Study Procedure', 'and 2\u00b9', 'Assessments\u00b2', 'Survival status', 'X', 'Limited physical exam\u00b3', 'X', 'Concomitant medications', 'X', 'Vital signs', 'X', 'Electrocardiogram', 'X', 'Adverse events', 'X', 'Laboratory Testing', 'Hematology', 'X', 'Blood chemistry', 'X', 'Pregnancy test for WOCBP', 'X', 'TSH (with reflex T3, free T4)', 'X', 'ADA', 'X4', 'PK', 'X4', 'Soluble biomarkers (serum/plasma)', 'X', 'PBMC (optional)', 'X6', 'Quality of Life', 'EORTC QLQ-C30', 'X', 'Efficacy (Radiology)', 'CT and/or MRI5', 'X', 'X', '7.1.5.', 'Footnotes for the Schedule of Events Table for Post-Treatment Follow-up', '1. Post-treatment follow-up pertains to all patients (both treatment groups). This pertains to', 'patients who completed all 16 cycles of planned treatment, and to patients who discontinue', 'treatment prior to the completion of 16 cycles. Follow-up visit 1 occurs approximately', '30 days (10 days) from last dose of cemiplimab or IC of chemotherapy. Follow-up visit', '2 occurs approximately 90 days (10 days) after follow-up visit 1.', 'Regeneron Pharmaceuticals, Inc.', 'Page 56 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '2. After the end of study, survival follow-up assessments will occur every 90 days (+10 days)', 'until death or study termination per sponsor and GOG. It is preferable for survival follow-up', 'assessments to occur in the clinic, but telephone assessments are acceptable. Regeneron may', 'request that survival data be collected on all randomized participants outside of the 90-day', 'specified window. At the time of this request, each participant will be contacted to determine', 'their survival status unless the patient has withdrawn consent for all contact.', '3. Limited physical exam includes heart, lung, abdomen, and skin.', '4. During the follow-up period, after end of treatment of cemiplimab, PK and ADA samples', 'are collected at follow-up 1 visit. PK and ADA samples may be collected at follow-up', 'visit 2 (approximately 4 months post last treatment of cemiplimab). In response to adverse', 'events of special interest (AESIs), such as anaphylaxis or hypersensitivity, ADA samples', 'may be collected closer to the event, based on the judgment of the investigator and/or', 'medical monitor.', '5. Radiologic imaging in the post-treatment follow-up period is only required for patients who', 'have not experienced prior PD. Tumor assessments should occur every 90 days (10 days)', 'until PD.', '6. PBMC samples are to be obtained only from patients randomized to receive cemiplimab and', 'have signed optional PBMC consent.', '7.1.6.', 'Option for Retreatment', 'Patients who complete 16 cycles of treatment (Table 1) enter the follow up period (Table 2). If', 'they have not experienced PD during the study, radiologic assessments will continue until PD, as', 'per Table 2. If a patient experiences PD during the follow-up period, retreatment with the same', 'drug that was given during the treatment period is an option. A patient who was initially', 'randomized to receive cemiplimab may be considered for resumption of cemiplimab. A patient', 'who was initially randomized to IC of chemotherapy may be considered for resumption of the', 'same chemotherapy that they received in the treatment period. Resumption of treatment due to', 'PD during the follow-up period may be allowed if:', 'The patient received no other anticancer systemic therapy during the follow-up period.', 'The reason for discontinuation of study treatment was the completion of 16 planned', 'cycles, not for toxicity.', 'The patient provides written informed consent prior to initiating retreatment by signing', 'the current version of the ICF (eg, the patient repeats the written informed consent', 'process that was performed prior to study enrollment).', 'All screening period assessments (with the exception of providing tumor pathology', 'material) are repeated, and the patient meets all study eligibility criteria (with the', 'exception of the exclusion regarding prior anti-PD-1 therapy if the patient was', 'randomized to cemiplimab).', 'Patients who resume study treatment will follow the schedule of events in Table 1, for up to', '8 cycles total with the same treatment to which they were originally randomized. Cycles will be', 'counted as 17 through 24. However, PK, ADA, research blood samples, and PBMC samples are', 'Regeneron Pharmaceuticals, Inc.', 'Page 57 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}